Vladimir J N Bykov Selected Research

Therapeutics

1/2023	Novel compounds that synergize with aminoglycoside G418 or eRF3 degraders for translational readthrough of nonsense mutant TP53 and PTEN.
1/2021	A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death.
12/2018	The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells.
10/2018	Role of Thiol Reactivity for Targeting Mutant p53.
1/2018	APR-246 reactivates mutant p53 by targeting cysteines 124 and 277.
1/2018	Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246.
1/2018	Targeting mutant p53 for efficient cancer therapy.
1/2017	Synergistic Rescue of Nonsense Mutant Tumor Suppressor p53 by Combination Treatment with Aminoglycosides and Mdm2 Inhibitors.
1/2016	Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy.
5/2010	The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Vladimir J N Bykov Research Topics

Disease

21	Neoplasms (Cancer) 01/2023 - 03/2002
2	Breast Neoplasms (Breast Cancer) 01/2023 - 12/2018
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 08/2022 - 01/2021
2	Hematologic Neoplasms (Hematological Malignancy) 01/2021 - 10/2012
2	Ovarian Neoplasms (Ovarian Cancer) 12/2018 - 01/2016
1	Astrocytoma (Pilocytic Astrocytoma) 01/2023
1	Retinoblastoma (Glioblastoma, Retinal) 01/2023
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2021
1	Cataract (Cataracts) 10/2018
1	Open-Angle Glaucoma (Glaucoma, Open Angle) 10/2018
1	Glaucoma 10/2018
1	Prostatic Neoplasms (Prostate Cancer) 10/2012
1	Uveal melanoma 07/2012
1	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 07/2008
1	Hepatocellular Carcinoma (Hepatoma) 07/2008

Drug/Important Bio-Agent (IBA)

8	eprenetapoptIBA 08/2022 - 05/2005
5	DNA (Deoxyribonucleic Acid)IBA 01/2018 - 01/2003
4	Proteins (Proteins, Gene)FDA Link 11/2022 - 12/2002
4	2,2- bis(hydroxymethyl)- 1- azabicyclo(2,2,2,)octan- 3- oneIBA 05/2010 - 12/2002
2	AminoglycosidesIBA 01/2023 - 01/2017
2	Nonsense Codon (Nonsense Mutation)IBA 01/2023 - 11/2022
2	Fluorouracil (Carac)FDA LinkGeneric 11/2022 - 10/2018
2	Asparaginase (Elspar)FDA Link 08/2022 - 01/2021
2	Sulfhydryl Compounds (Thiols)IBA 01/2021 - 01/2018
2	maleimideIBA 12/2017 - 08/2005
2	CP 31398IBA 06/2008 - 03/2002
1	Complementary DNA (cDNA)IBA 01/2023
1	antibiotic G 418IBA 01/2023
1	Retinoblastoma ProteinIBA 01/2023
1	5-fluorouridineIBA 11/2022
1	AsparagineIBA 01/2021
1	multidrug resistance-associated protein 1IBA 01/2021
1	RNA (Ribonucleic Acid)IBA 12/2018
1	Tetracycline (Achromycin)FDA LinkGeneric 08/2005
1	1-(propoxymethyl)maleimideIBA 08/2005
1	Cisplatin (Platino)FDA LinkGeneric 05/2005
1	Transcription Factors (Transcription Factor)IBA 01/2003

Therapy/Procedure

12	Therapeutics 01/2023 - 01/2003
1	Percutaneous Collagen Induction 10/2018
1	Intravenous Infusions 10/2012
1	Treatment Delay 07/2008
1	Radiotherapy 08/2005
1	Drug Therapy (Chemotherapy) 08/2005